Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Triple Negative Breast Neoplasms Clinical Trial

Official title:

A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03838367
• Other study ID #: CD07_TNBC
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: April 22, 2019
• Est. completion date: September 16, 2022

Study information

• Verified date: September 2021
• Source: CytoDyn, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC).

Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).

Description:

Phase Ib

Phase Ib is a dose escalation phase with 3 dose levels (cohorts) of leronlimab (PRO 140) administered in combination with a fixed dose of carboplatin at AUC 5. This dose finding portion of study will follow a "3+3" designed to determine the maximum tolerated dose (MTD) of leronlimab (PRO 140) administered as subcutaneous injection in subjects with histologically confirmed mTNBC that express CCR5.

Phase II

Phase II is a single arm study with 30 patients in order to test the hypothesis that the combination of carboplatin AUC 5 intravenously and MTD of leronlimab (PRO 140) SC will increase PFS in patients with CCR5 + mTNBC.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 48
• Est. completion date: September 16, 2022
• Est. primary completion date: July 15, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Must have a histologically confirmed diagnosis of TNBC. Must demonstrate HER-2 negative (IHC 0, 1+, or fluorescence in situ hybridization (FISH) negative and ER<1%, and PR < 1%, per ASCO/CAP criteria);

2. Demonstrate CCR5 + by IHC (>10% membranous staining completed at the reference laboratory of Dr. Hallgeir Rui at Medical College of Wisconsin).

Note: This test will be done as part of the pre-screening period. It will be performed in archival metastatic tissue. If archival tissue is not available then, fresh biopsy will be done;

3. Be willing to provide tissue from a newly obtained core or excisional biopsy of a tumor lesion (in case archival tissue is not available);

4. Subjects must be untreated or naïve to chemotherapy and/or checkpoint inhibitors exposure in metastatic setting and have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line); Note: Patients who have been exposed to carboplatin in neoadjuvant or adjuvant setting will be allowed to enroll, if they have progressed = 6 months from completion of treatment.

5. Patients must have measurable disease based on RECIST v1.1;

6. Female patients, = 18 years of age;

7. Patients must exhibit a/an ECOG performance status of 0-1;

8. Life expectancy of at least 6 months;

9. Patients must have adequate organ and bone marrow function within 28 days prior to registration, as defined below:

• leukocytes = 3,000/mcL;

• absolute neutrophil count = 1,500/mcL;

• platelets = 100,000/mcL;

• total bilirubin: within normal institutional limits;

• AST(SGOT) &ALT(SPGT) = 2.5 X institutional upper limit of normal (ULN) (applicable to all patients, irrespective of liver disease or metastasis); and

• creatinine: within normal institutional limits.

10. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator.

11. Females of child-bearing potential (FOCBP) and males must agree to use two medically accepted methods of contraception with hormonal or barrier method of birth control, or abstinence, prior to study entry, for the duration of study participation and for 60 days after the last dose of study drug (Refer to Appendix 1). Should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

• Has not undergone a hysterectomy or bilateral oophorectomy; and

• Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months).

12. FOCBP must have a negative serum pregnancy test at Screening Visit and negative urine pregnancy test prior to receiving the first dose of study drug; and

13. Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study.

Exclusion Criteria:

1. HER-2 overexpressed/amplified MBC (Appendix 2 for guidelines from ASCO);

2. ER and or PR expressing tumors;

3. Subjects who have had previous systemic chemotherapy for metastatic breast cancer;

4. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 28 days prior to enrollment;

5. Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (PRO 140) are not eligible;

6. Patients who have had prior exposure to CCR5 antagonists are not eligible;

7. Patients who have a known additional malignancy that is progressing or requires active treatment are not eligible. Patients who have had a prior diagnosis of cancer and if it has been <3 years since their last treatment are not eligible. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer;

8. Has an active infection requiring systemic therapy. Note: Patients must complete any treatment with antibiotics prior to registration;

9. Patients who have a known HIV positive status or known/ active Hepatitis B and/or C infection are not eligible;

10. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Note: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability;

11. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator;

12. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial; and

13. Is pregnant or breastfeeding, or expecting to conceive or have children within the projected duration of the trial, starting with the pre-screening or screening visit through the duration of study participation.

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Neoplasms

Intervention

Drug:
• 350 mg leronlimab
leronlimab is a humanized IgG4,? monoclonal antibody (mAb) to the chemokine receptor CCR5.
• 525 mg leronlimab
leronlimab is a humanized IgG4,? monoclonal antibody (mAb) to the chemokine receptor CCR5.
• 700 mg leronlimab
leronlimab is a humanized IgG4,? monoclonal antibody (mAb) to the chemokine receptor CCR5.
• AUC 5 Carboplatin
Carboplatin is an anticancer drug chemotherapy drug.
• Maximum Tolerated Dose (MTD) of leronlimab
The decision on the MTD will be made following the results obtained from Phase I studies

Locations

Country	Name	City	State
United States	CD07 Investigational Site	Chicago	Illinois
United States	Quest Clinical Research	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
CytoDyn, Inc.	Amarex Clinical Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Measure immune biomarkers (PD-L1) in CTCs, metastatic tissue and immune cells such as CAMLs and correlate with therapeutic benefit (PFS)		Every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.
Other	Correlation between CCR5 expression (CTCs, CAMLs) and PD- L1 expression.		Every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.
Primary	Phase Ib: Maximum Tolerated Dose (MTD) of leronlimab (PRO 140) when combined with carboplatin AUC5		Cycle 1 (21 days)
Primary	Phase II: Progression free survival (PFS) defined as time in months from the date of first study treatment to the date of disease progression or death from any cause, whichever comes first.		Every 6 to 9 weeks after study start, until progression or death, assessed up to 2 years after completion of treatment
Secondary	Phase I: The number, frequency, and severity of adverse events (AEs) collected from the time of first treatment until 12 weeks after study treatment completion to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ mTNBC.		From Cycle 1, Day 1 (each treatment cycle is 21 days) to 12 weeks after the last dose of study drug)
Secondary	Phase II: Progression Free Survival (PFS) according to RECIST v1.1 in participants with Detectable Programmed Death-Ligand 1 (PD-L1)		Every 6 to 9 weeks after study start, until progression or death, assessed up to 2 years after completion of treatment
Secondary	Phase II: Overall response rate (ORR, defined as Complete Response (CR) + Partial Response (PR)), and clinical benefit rate (CBR, defined as CR + PR + Stable Disease (SD)) in subjects with CCR5+ mTNBC treated with leronlimab (PRO 140) and carboplatin.		Every 6 to 9 weeks after study start, until progression or death, assessed up to 2 years after completion of treatment
Secondary	Phase II: Time to new metastases (TTNM)		Every 6 to 9 weeks after study start, until progression or death, assessed up to 2 years after completion of treatment
Secondary	Phase II: The change from baseline in circulating tumor cells (CTC) level in the peripheral blood.		Every 21 days (i.e., Day 1 of each treatment cycle) through treatment completion, an average of 6 months.
Secondary	Phase II: Overall survival defined as time in months from the date of first study treatment to the date of death;		From Day 1 to death from any cause, assessed up to 2 years after completion of treatment.
Secondary	Phase II: The number, frequency, and severity of AEs collected from the time of first treatment until 12 weeks after study treatment completion to evaluate safety of leronlimab (PRO 140) and carboplatin in subjects with CCR5+ mTNBC.		From Cycle 1, Day 1 (each treatment cycle is 21 days) to 12 weeks after the last dose of study drug)